A total of 66 bladder cancer patients were studied to establish if relationships exist between HER-2/neu alteration and pathological stage and grade and to define a subgroup of patients with poor prognosis in terms of time to recurrence, time to progression and survival. Tumor and healthy tissue specimens were analyzed for HER-2/neu DNA amplification and protein over-expression by Southern and Western blot techniques. Results were analysed statistically. 13% cases were amplified and 39% over-expressed. HER- 2/neu alterations were not significantly associated with pathological staging or tumor grading. Multifocal tumors had a higher percentage and more over- expression than monofocal tumors. Actuarial analyses did not show a significant correlation between HER-2/neu amplification, over-expression and clinical outcome. Clinical assessment of HER-2/neu status showed this gene is not related to tumor relapse, progression or patient survival.
|Number of pages||6|
|Journal||Acta Urologica Italica|
|Publication status||Published - 1999|
- Bladder cancer
ASJC Scopus subject areas